Filing Flows › Comparisons › DTIL vs VXRT
Precision Biosciences vs Vaxart: DTIL and VXRT compared
Precision Biosciences is the larger company: $10.8M of revenue in its latest quarter (Q3 FY26) against $10.6M for Vaxart (Q3 2026). Precision Biosciences is growing faster (374× against -85% a year earlier). Precision Biosciences is more profitable, with an operating margin of -83.7% against -162.7%.
Where the money goes: DTIL and VXRT
Precision Biosciences (DTIL) · Q3 FY26
Precision Biosciences, Q3 FY26: revenue $10.8M (374× year over year), operating margin -83.7%, net loss $18.4M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
Vaxart (VXRT) · Q3 2026
Vaxart, Q3 2026: revenue $10.6M (-85% year over year), operating margin -162.7%, net loss $17.7M, operating cash flow $1.4M. The chart follows the revenue to costs, profit and cash.
| Precision Biosciences (DTIL) | Vaxart (VXRT) | |
|---|---|---|
| Latest quarter | Q3 FY26 | Q3 2026 |
| Revenue | $10.8M | $10.6M |
| Revenue growth, Y/Y | 374× | -85% |
| Operating margin | -83.7% | -162.7% |
| Net earnings | −$18.4M | −$17.7M |
| Net margin | -170.2% | -166.6% |
| Operating cash flow | −$11.9M | $1.4M |
| Free cash flow | — | $1.1M |
Where the revenue comes from
Vaxart
- Government Contract: $7.5M (71%)
- Collaboration Revenue: $2.9M (28%)
- Non Cash Royalty Revenue: $154K (1%)
Questions
Which is bigger, Precision Biosciences or Vaxart?
Precision Biosciences is the larger company: $10.8M of revenue in its latest quarter (Q3 FY26) against $10.6M for Vaxart (Q3 2026).
Is Precision Biosciences or Vaxart growing faster?
Precision Biosciences is growing faster (374× against -85% a year earlier).
Which is more profitable, Precision Biosciences or Vaxart?
Precision Biosciences is more profitable, with an operating margin of -83.7% against -162.7%.
More: Precision Biosciences earnings · how Precision Biosciences makes money · Vaxart earnings · how Vaxart makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 5, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.